For everyone shitting on
@Cracker69 's post, ie.
@IronLion2 @tren_plz
My suggestion is next time something seemingly dissonant with your worldview is brought to your attention, that a little more effort go into exploring and researching it, before casting it off with undue certainty.
From the 2019 study here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468406/
"
Although diet and exercise should always be the first line of defense,
DNP appears to mimic in part the neuroprotective and neurorestorative effects of exercise and fasting by increasing BDNF, lowering cellular stress and building cellular resiliency by mild increases in mitochondrial bioenergetics.
...
It is possible that the increase in cAMP is also due to an inactivation of phosphodiesterases (PDEs) that degrades cyclic nucleotides as well. PDE inhibitors have been sought after to improve cognition, reduce episodes of schizophrenia, depression and improve mental stability with the rise of cAMP, which DNP treatment may address as well [
181,
182].
The collective benefits of DNP driven increases of cAMP, CREB and BDNF may be vast for mental health. Treatment of animals representing a myriad of human neurodegenerative diseases with DNP appears pro-neuroprotective for diseases of known and unknown etiology, and indications of all ages (pediatrics, adult and elderly). It is not a “magical elixir”, but based upon the scientific fact that: 1) all human cells have mitochondria except mature red blood cells, 2) they have a symbiotic relationship within the cell governing cell survival and functions that impact many pathways, and 3) from experimental studies in so many laboratories across the world that have compiled both
positive and significant data showing its merit in animal models of Huntington Disease, Parkinson Disease, Alzheimer’s Disease, Multiple Sclerosis, Rett Syndrome (data not shown), epilepsy, hearing loss, vision loss (optic neuritis), traumatic brain injury, and Duchenne Muscular Dystrophy [
28,
52,
85,
86]. Others have tested DNP in models of stroke, sciatic nerve injury, TBI, Aβ1-42 inhibition of plaque formation and various metabolic diseases [
29,
45,
87,
88,
164,
167,
183]. This spectrum corresponds to diseases of developmental (Rett), neuromuscular (DMD), metabolic (NASH, diabetes, insulin resistance), neurodegeneration (AD, PD, HD, etc.), autoimmune (MS, ON, etc.) and trauma (hearing, stroke, nerve damage, TBI) (
Figure 7).
...
DNP (MP101) or the prodrug of DNP (MP201) has been tested in disease models of acute and chronic studies with a known and unknown genetic cause that representing pediatric, adult and elderly indications with statistically positive outcomes. The indications also present diseases of neuromuscular disorders, development, neurodegeneration, autoimmune, metabolic and trauma. The future will help to determine the limitations of the pharmacology, but given the findings,
it appears that DNP may be a broad-spectrum treatment to many disorders.
...
Collectively, DNP may be a treatment for an emerging global term called “metabesity” referring to all the co-morbidities associated with the over-nutritional phenotype such an increased incidence of insulin resistance, obesity, type 2 diabetes, sleep apnea, depression, inflammation, cardiovascular disease, hypertension, non-alcoholic fatty liver disease, but includes accelerated aging, neurodegeneration, and cancer. [
2,
184,
185]. Studies are underway to explore an ever-expanding application of low dose mitochondrial uncoupling pharmacology. There are other insidious diseases like Pompe, Wolfram Syndrome, Friedreich ataxia, cardiolipin production, etc., that are associated with mitochondrial dysfunction of Ca2+, ATP and ROS homeostasis, that have no cures, so it is important to understand if DNP or modified versions of DNP may have merit in these diseases as well [
15,
43,
46,
186,
187,
188].
Since DNP was tested in many laboratories, for completely diverse indications, it speaks to the idea that modulating mitochondrial physiology with uncouplers, can enlist cellular resiliency that is global to many diseases. Therefore, when it comes to mulling on whether a particular disease has a mitochondrial component and whether or not DNP could have merit, it is imperative that it just gets tested.
...
The metabolic impact of raising energy expenditure by a small degree to partition fat out of the insulin-sensitive tissues (liver and muscle), could, in fact, emerge as a method of treatment for the intractable over-nutritional phenotype at safe, weight
neutral doses (
Figure 8) [
2,
189].
Since weight neutral doses of DNP significantly raises BDNF, which also has anti-diabetic properties in peripheral organs, there may be a synergistic effect of clearing lipids while raising BDNF [
70,
71,
72,
73,
190]. This approach is significantly safer than the approach in the 1930s, as
doses would be at least 10–60× lower [
52].
...
The dose window that we have seen with all the animal studies has been between ~0.5–5 mg/kg in mice,
which correlates to a HED range between ~2–22 mg/day. If this translates to the human scenario, including the hormetic response, then it would not make sense to push the dose for instance to 22 mg for AD, which corresponds to 5 mg/kg in the mouse model, when it was clearly shown that 0.5 mg/kg or less in the APP/PS1 was optimal,
a HED of 2 mg/day or lower.
...
The progress that has been made in the science of mitochondrial bioenergetics has been tremendously important to gain an understanding of the central role in the cell that this organelle governs over so many pathways. The acceleration of mitochondrial research in the last couple of decades and an emerging focus on the legion of diseases is remarkable. With over 80 years since DNP has been in a clinical study, there is also a tremendous opportunity to learn today what merits the pharmacology may provide repositioned for truly insidious diseases using modern day clinical practices. This approach is a much lower hanging fruit than the very high hurdles of gene replacement as a first line of attack.
It is possible to wake up redundant cellular compensatory mechanisms by modulating the mitochondria’s entire physiology towards pro-survival of the cell, with a brain penetrant, simple oral dosing of DNP to attenuate disease progression for a broad number of indications, slow aging, and the potential in the future to prophylactically treat patients to entirely prevent the myriad of age-related illnesses. It may sound unorthodox, but it falls within the physiology/pharmacology of the mechanism of action to be plausibly true.
"